Only 1 of 25 cancer drug developers fairly included minority patients over five-year window, BMJ analysis finds
[ad_1] New clinical trial diversity plans, which FDA will soon explain further, were featured in the government spending package that President Joe Biden signed late last week and are coming […]




















